Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Famotidine

This article was originally published in The Tan Sheet

Executive Summary

FDA approves ANDA 75-512 for Ivax' generic equivalent to J&J/Merck's Pepcid AC July 26, Miami-based company reports. Ivax famotidine 10 mg is first to carry heartburn prevention claim. Teva Pharmaceuticals received ANDA approval for a heartburn treatment claim May 31, according to FDA; firm licenses its version to Perrigo for sale in U.S. (1"The Tan Sheet" June 4, p. 7). Cheminor Drugs and Danbury Pharmacal have received tentative approval

You may also be interested in...



Perrigo Famotidine Approved With Six Month Exclusivity; Shipments Begin

Perrigo's private label famotidine 10 mg was approved by FDA May 31, ending a drawn out delay of the generic launch.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS092844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel